Wojciech Zareba MD, PhDDirector, Heart Medicine, Department of Medicine, Cardiology, Professor, Heart Research, University of Rochester Medical Center, Rochester, NY
Wojciech Zareba, MD, PhD, is a Professor of Medicine (Cardiology), Director of the Heart Research Follow Up Program at University of Rochester Medical Center, Rochester, NY.
Dr. Zareba is Principal Investigator or Co-PI on several NIH and corporate grants focused on the risk stratification of cardiac death, testing therapies to decrease risk of cardiac arrhythmias, and on clinical usefulness and prognostic significance of ECG parameters. Studies with his role as PI or Co-PI include: International LQTS Registry, the North American ARVD Registry, MADIT trials, RAID trial, TEMPO trial and several other studies focused on risk stratification. He also serves as Principal Investigator of the ECG Core Labs for numerous studies and clinical trials. He participated in a number of corporate research projects focused on evaluating drug safety and participated in a number of advisory councils on the topic of cardiac safety in drug trials.
Dr Zareba has authored or co-authored more than 500 publications in cardiology research with many of them focused on sudden death, risk stratification, QT prolongation, device therapy, heart failure, and ECG related cardiac safety biomarkers. Dr. Zareba is Past President of the International Society for Holter and Noninvasive Electrocardiology and President Elect of The International Society of Electrocardiology. Dr. Zareba has been serving for 7 years as the Editor in Chief of Cardiology Journal, and currently is Editor in Chief of the Annals of Noninvasive Electrocardiology as well as a member of the editorial boards of a number of other leading cardiology-related journals.
Recent Contributions to PracticeUpdate:
- Clinical Effectiveness of Primary Prevention ICDs
- Effects of ICD Programming in Concordance With Guidelines on Outcomes
- New-Onset Left Bundle Branch Block After TAVR Is Associated With Adverse Long-Term Clinical Outcomes in Intermediate-Risk Patients
- Ranolazine in High-Risk Patients With ICDs
- Changes in LVEF and Associated Outcomes in Primary Prevention ICD Recipients
- Predicting Proportional Risk From Sudden Cardiac Death in HF